Equities research analysts at StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The firm has a market cap of $6,000.00, a PE ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 12-month low of $0.00 and a 12-month high of $0.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.
Genocea Biosciences Company Profile
Further Reading
- Five stocks we like better than Genocea Biosciences
- Profitably Trade Stocks at 52-Week Highs
- 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
- What Are Dividend Challengers?
- These 3 Stocks Have Huge Last 12 Months Shareholder Yields
- Stock Market Upgrades: What Are They?
- Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.